Chad Brummett
Chad Brummett
The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery. The information collected in this study is necessary to help understand whether CBD may be a useful medication before and/or after surgery. The study hypothesis is that CBD exerts opioid-sparing effects through anti-inflammatory, analgesic, and anxiolytic mechanisms.
Knee Replacement Surgery
Osteoarthritis, Knee
Epidiolex oral solution
Placebo
PHASE2
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 380 participants |
Masking : | TRIPLE |
Masking Description : | The participants and the study team at each site will be blinded except for the site research pharmacist and the site project manager (PM) and/or PM delegate. |
Primary Purpose : | TREATMENT |
Official Title : | Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty - a Randomized, Two by Two Factorial, Double-blind, Placebo-controlled Clinical Trial |
Actual Study Start Date : | 2024-03-13 |
Estimated Primary Completion Date : | 2029-01 |
Estimated Study Completion Date : | 2029-01 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 80 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University of Michigan
Ann Arbor, Michigan, United States, 48109
NOT YET RECRUITING
Henry Ford Health System
Detroit, Michigan, United States, 48202